Wealth Effects’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Wealth Effects’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,365	Closed	-$32.1K	–	226
2024 Q2	$32.1K	Sell	3,365 -281	-8%	-$9.47K	0.01%	204
2024 Q1	$276K	Buy	3,646 +1,860	+104%	+$245K	0.1%	160
2023 Q4	$318K	Buy	1,786 +847	+90%	+$417K	0.12%	147
2023 Q3	$663K	Buy	939 +516	+122%	+$2.21M	0.33%	74
2023 Q2	$1.94M	Buy	423 +174	+70%	+$604K	0.85%	14
2023 Q1	$661K	Buy	+249	New	+$729K	0.34%	71

Other funds holding SEEL

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

MWM

Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CHA

Carmichael Hill & Associates Gaithersburg, Maryland $282M AUM 32.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Wealth Effects's SEEL Position: Q3 2024 in Review

Wealth Effects sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2024, closing a stake of 3,365 shares — an estimated $32.1K sold.

Wealth Effects first reported a position in SEEL in Q1 2023 and held it in 6 quarters. The position peaked at $1.94M in Q2 2023. 15 funds tracked by Wall St. Rank hold SEEL as of Q3 2024.

Wealth Effects reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Wealth Effects sold 3,365 Seelos Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $32.1K.
Wealth Effects first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2023 and held it in 6 quarters.
Wealth Effects's Seelos Therapeutics, Inc. Common Stock position peaked at $1.94M in Q2 2023.
15 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Wealth Effects's 13F filing for Q3 2024, filed 21 Oct 2024.